Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Illumina (ILU) Stock Price & Analysis

1 Followers

ILU Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 26.25B
Enterprise Value
CHF 42.56B
Total Cash (Recent Filing)
CHF 1.34B
Total Debt (Recent Filing)
CHF 2.31B
Price to Earnings (P/E)
35.1
Beta
N/A
Next Earnings
Feb 11, 2027 (Est.)
EPS Estimate
1.26
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Recurring Consumables Base

Illumina’s expanding NovaSeq X installed base strengthens the recurring consumables model because customers must continue purchasing reagents and flow cells to use their instruments. This creates revenue pull-through, improves customer retention, and supports durable growth beyond initial system placements.

Clinical Growth

Strong clinical consumables growth indicates sequencing is gaining adoption in tests and clinical trials, a potentially durable end market. Continued mid-teens growth expectations and a rich pipeline of new tests provide a foundation for expanding utilization and recurring revenue.

Cash Generation And Margins

Recent profitability and strong free cash flow give Illumina meaningful internal funding capacity for product development, commercial investment, and balance-sheet needs. High gross margins and solid earnings conversion also support the quality of current results, provided performance remains durable.

Bears Say

Research Market Decline

Weakness in research and applied consumables offsets clinical momentum and limits consolidated growth. Because these markets remain an important part of sequencing demand, continued declines could reduce instrument utilization, delay customer purchases, and pressure revenue mix over the next several quarters.

Pricing And Cost Headwinds

Persistent pricing and input-cost pressure can constrain margin expansion even as operating execution improves. The NovaSeq X transition also includes a price step-down, so sustained cost inflation or unfavorable pricing could reduce the economic benefit of growing volumes and installed-base utilization.

Earnings Volatility

The sharp multi-year swings in profitability make Illumina’s earnings power less predictable than its recent rebound suggests. Such volatility can complicate planning and capital allocation, while another demand or execution setback could materially weaken margins and cash generation.

Illumina News

ILU FAQ

What is Illumina’s market cap?
Illumina’s market cap is CHF26.25B.
When is Illumina’s upcoming earnings report date?
Illumina’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 88 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Oct 29, 2026. The company reported CHF1.189 earnings per share for the quarter, beating the consensus estimate of CHF1.119 by CHF0.069.
Is Illumina overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.26.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of CHF1.189 in its last earnings report, beating expectations of CHF1.119. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Illumina?
Hedge funds hold Illumina shares: the largest hedge-fund position in Illumina is 287,069,619 shares, and hedge funds decreased their holdings by 789.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology